28466-21-9

Basic information

• Product Name: 4-AMINO-1,3,5-TRIMETHYLPYRAZOLE
• Synonyms: TIMTEC-BB SBB006986;AKOS PAO-0230;AKOS B000505;4-AMINO-1,3,5-TRIMETHYLPYRAZOLE;1,3,5-TRIMETHYL-1H-PYRAZOL-4-AMINE;1,3,5-TRIMETHYL-1H-PYRAZOL-4-YLAMINE;BUTTPARK 29\06-78;ART-CHEM-BB B000505
• CAS NO: 28466-21-9
• Molecular Formula: C₆H₁₁N₃
• Molecular Weight: 125.17
• EINECS: -0
• Mol File: 28466-21-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 96 °C
• Boiling Point: 236℃
• Flash Point: 97℃
• Appearance: brown solid
• Density: 1.13
• Vapor Pressure: 0.048mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.75±0.10(Predicted)
• BRN: 110739
• CAS DataBase Reference: 4-AMINO-1,3,5-TRIMETHYLPYRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-1,3,5-TRIMETHYLPYRAZOLE(28466-21-9)
• EPA Substance Registry System: 4-AMINO-1,3,5-TRIMETHYLPYRAZOLE(28466-21-9)

Safety Data

• Hazard Codes: Xi
• Safety Statements: S22:Do not inhale dust.; S24/25:Avoid contact with skin and eyes.
• RTECS: UQ6125100
• Hazardous Substances Data: 28466-21-9(Hazardous Substances Data)

Usage

General Description

4-AMINO-1,3,5-TRIMETHYLPYRAZOLE is a chemical compound with the molecular formula C6H10N4. It is a pyrazole derivative that is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. 4-AMINO-1,3,5-TRIMETHYLPYRAZOLE is classified as an amino compound, meaning it contains an amine group (-NH2) and is also substituted with three methyl groups. 4-AMINO-1,3,5-TRIMETHYLPYRAZOLE is known for its high stability and reactivity, making it a valuable intermediate in the production of various active ingredients for different applications. Additionally, it has been studied for its potential use in the development of new materials and chemical processes.

InChI:InChI=1/C6H11N3/c1-4-6(7)5(2)9(3)8-4/h7H2,1-3H3

Upstream product

• 67-51-6 3,5-dimethyl-1H-pyrazole 
• 15801-69-1 4-bromo-1,3,5-trimethylpyrazole 
• 14531-55-6 3,5-dimethyl-4-nitro-1H-pyrazole 
• 1123-49-5 3,5-dimethyl-4-nitroisoxazole 
• 29917-12-2 Isonitrosoacetylacetone 
• 7171-70-2 1,3,5-trimethyl-4-nitrosopyrazole 
• 1125-30-0 1,3,5-trimethyl-4-nitro-1H-pyrazole 

Downstream Products

• 107203-65-6 (4-dimethylamino-benzylidene)-(1,3,5-trimethyl-1H-pyrazol-4-yl)-amine 
• 100373-74-8 benzylidene-(1,3,5-trimethyl-1H-pyrazol-4-yl)-amine 
• 1215013-68-5 4-bromomethyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide 
• 1215011-39-4 3'-dimethylaminomethylbiphenyl-4-sulfonic acid (1,3,5-trimethyl-1H-pyrazol-4-yl)amide 
• 1215011-34-9 4-[3-(4-methylpiperazin-1-yl)-prop-1-ynyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide 
• 1215011-28-1 3'-piperidin-4-yl-biphenyl-4-sulfonic acid (1,3,5-trimethyl-1H-pyrazol-4-yl)amide 
• 1215011-27-0 4-(2-[1,4]-diazepan-1-yl-pyridin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide 

Relevant articles and documents

BICYCLIC KINASE INHIBITORS AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions of the invention may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN-RELATED PEPTIDASE 6 (KLK6)

The invention relates to compounds which are suitable for the treatment of a disease associated with kallikrein-like peptidase 6 overexpression and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds or pharmaceutical compositions.

COMPOUNDS

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).